跳转至内容
Merck
CN
  • Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis.

Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis.

Nature communications (2021-06-10)
Joshua D G Leach, Nikola Vlahov, Petros Tsantoulis, Rachel A Ridgway, Dustin J Flanagan, Kathryn Gilroy, Nathalie Sphyris, Ester G Vázquez, David F Vincent, William J Faller, Michael C Hodder, Alexander Raven, Sigrid Fey, Arafath K Najumudeen, Douglas Strathdee, Colin Nixon, Mark Hughes, William Clark, Robin Shaw, Sander R van Hooff, David J Huels, Jan Paul Medema, Simon T Barry, Margaret C Frame, Asier Unciti-Broceta, Simon J Leedham, Gareth J Inman, Rene Jackstadt, Barry J Thompson, Andrew D Campbell, Sabine Tejpar, Owen J Sansom
摘要

Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair and TGFβ signalling. Here, we describe a mouse model of right-sided colon cancer driven by oncogenic BRAF and loss of epithelial TGFβ-receptor signalling. The proximal colonic tumours that develop in this model exhibit a foetal-like progenitor phenotype (Ly6a/Sca1+) and, importantly, lack expression of Lgr5 and its associated intestinal stem cell signature. These features are recapitulated in human BRAF-mutant, right-sided CRCs and represent fundamental differences between left- and right-sided disease. Microbial-driven inflammation supports the initiation and progression of these tumours with foetal-like characteristics, consistent with their predilection for the microbe-rich right colon and their antibiotic sensitivity. While MAPK-pathway activating mutations drive this foetal-like signature via ERK-dependent activation of the transcriptional coactivator YAP, the same foetal-like transcriptional programs are also initiated by inflammation in a MAPK-independent manner. Importantly, in both contexts, epithelial TGFβ-receptor signalling is instrumental in suppressing the tumorigenic potential of these foetal-like progenitor cells.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
泰莫西芬, ≥99%
Sigma-Aldrich
异硫氰酸荧光素-葡聚糖, average mol wt 4,000, (FITC:Glucose = 1:250)
Sigma-Aldrich
CHIR99021, ≥98% (HPLC)
Sigma-Aldrich
氨苄西林 钠盐
Sigma-Aldrich
丙戊酸 钠盐, 98%
Sigma-Aldrich
甲硝唑, BioXtra